Asston Pharmaceuticals IPO: GMP, Overview, And Price

Asston Pharmaceuticals IPO- Complete Overview

Asston Pharmaceuticals IPO under the SME IPO category is a book build issue of Rs. 27.56 Cr by Asston Pharmaceuticals Limited. The company was established in 2019 and is actively involved in the pharmaceutical industry and specialises in the international trade of healthcare products.

This company provides products in the form of tablets, capsules, syringes, and even syrups. Therageneric's range of products includes some of the most useful items in the medical field, like analgesics, antibiotics, antifungals, and even several vitamins.

Since the company works on a principal-to-principal basis with various marketers, it means that these companies produce products for direct sales and also on a contract or licensed manufacturing basis.

Products:

• Ibuprofen and Paracetamol

• Albendazole USP 400 mg

• Diclofenac 100 mg

• Ferrovit Syrup

 

Asston Pharmaceuticals IPO Overview

The Asston Pharmaceuticals IPO date is on 09 July 2025, and its initial public offering will end on 11 July 2025. 

The Rs. 27.56 Cr new SME IPO comprises a fresh issue of 22.41 lac Shares. The Asston Pharmaceuticals IPO price is Rs. 115 to Rs. 123 for each Share. 

The Asston Pharmaceuticals IPO listing date (expected) might be on Wednesday, Jul 16, 2025, and listing at the BSE and SME.

Click to open demat account and apply for the IPO.

Company Financial

(Amount in Cr)

Period	31 May 2025	31 Mar 2025	31 Mar 2024
Total Assets	31.83	28.12	20.26
Total Revenue	6.21	25.61	15.84
PAT	1.32	4.33	1.36
Net Worth	12.04	10.72	6.39
Reserves & Surplus	5.77	4.45	5.61
Borrowings	7.83	7.26	6.82

 

 

Cash Flows

(Amount in lac)

Net Cash Flow in Multiple Activities	31 May 2025	31 Mar 2025	31 Mar 2024
Net Cash Flow Operating Activities	(39.66)	(16.29)	(380.03)
Net Cash Flow Investing Activities	0	86.80	(0.54)
Net Cash Flow Financing Activities	41.25	(51.25)	368.84

 

Revenue Bifurcation

Geography-wise Revenue Bifurcation

(Amount in lac)

Medicine-wise Revenue Bifurcation

(Source: RHP)

The Objective of the Issue

The company desires to use the Net Proceeds from the Issue to fulfill its following goals:

• Financing the necessary capital expenditures for the manufacturing unit's machinery acquisition.

• Paying for the company's increased working capital needs.

• 3 Partial or complete repayment and/or prepayment of some of the company's outstanding borrowings.

• General corporate purposes.

 

Click to check the IPO application status.

Listed Peers of Asston Pharmaceuticals Ltd.

 

Company Name	Face Value (Rs.)	EPS (Rs.)	P/E (x)
Shelter Pharma Ltd.	10	6.26	6.70
Bafna Pharmaceuticals Limited	10	1.76	51.38
Trident Lifeline Ltd.	10	11.35	25.29

 

Evaluation

The Asston Pharmaceuticals Limited IPO price is Rs. 115 to Rs. 123 for each Share.

Evaluation of P/E Ratio

Considering the FY ended on 31 Mar 2025 with an EPS of Rs. 6.90 from the last year, the resulting P/E ratio is 17.82x.

Considering the weighted EPS of Rs. 4.55 for the last three years, the P/E ratio is 27.03x.

Explore the White Force IPO.

 

IPO's Strengths

• The proficiency in formulation.

• Experienced builders.

• A comprehensive range of merchandise.

• A strategic area served.

• Highly skilled workforce.

 

 

IPO’s Weaknesses

• Loss of some control over the manufacturing process with the contractor can lead to delay or total loss of the order, or even loss of customers.

• Being dependent on the contract manufacturer.

• Most of the revenues, however, to be generated from the international markets.

• We have working relations with one transporter only, i.e., Vision Container Lines.

 

Asston Pharmaceuticals IPO GMP

Asston Pharmaceuticals IPO GMP is Rs. 0 as of 04 Jul 2025 at the time of writing this information. Hence, its estimated listing price might be Rs. 123.

IPO Timetable (Tentative)

The Asston IPO date of opening is from Jul 09 to Jul 11, 2025, allotment on Jul 14, refund initiation on Jul 15, and listing on Jul 16, 2025.

Events	Date
IPO Opening Date	Jul 09, 2025
IPO Closing Date	Jul 11, 2025
IPO Allotment Date	Jul 14, 2025
Refund Initiation	Jul 15, 2025
IPO Listing Date	Jul 16, 2025

 

Asston Pharmaceuticals IPO Details 

The IPO with a Face Value of Rs. 10 per share offers a total issue size of 22,41,000 Shares (Rs. 27.56 Cr) with a market maker portion of 1,13,000 Shares (Rs. 1.39 Cr).

IPO Opening & Closing Date	09 Jul, 2025 to 11 Jul, 2025
Face Value	Rs. 10 per Share
Issue Price	Rs. 115 to Rs. 123 per Share.
Lot Size	1000 Shares
Issue Size	22,41,000 Shares (Rs. 27.56 Cr)
Offer for Sale	-
Fresh Issue	22,41,000 Shares (Rs. 27.56 Cr)
Listing at	BSE, SME
Issue Type	Book Built Issue
Registrar	Maashitla Securities Private Limited

 

 

IPO Lot Details 

Retail investors can invest in a minimum and maximum of 2 Lots (2000 Shares) for Rs. 2,46,000 and in multiples thereof, while for HNI investors, the minimum Lot is 3 (3000 Shares) for Rs. 3,69,000.

Minimum Lot Investment (Retail)	2 Lots
Maximum Lot Investment (Retail)	2 Lots
HNI (Min)	3 Lots

 

IPO Reservation (% of Net Issue)

Institutional’s Portion	47.30%
Retail’s Portion	33.29%
Non-Institutional Portion	14.37%

 

Promoters And Management of Asston Pharmaceuticals Ltd.

• Dr. Ashish Narayan Sakalkar

• Saili Jayaram More

• Sachin Chandrakant Badakh.
  
  

Pre-Issue Promoter Shareholding	68.76%
Post-Issue Promoter Shareholding	50.66%

 

IPO Lead Managers

• Sobhagya Capital Options Ltd.

 

 

Dividend Policy

The company has not declared dividends in the last three fiscal years.

Conclusion

Backed by a strong product portfolio and FDA-compliant operations, Asston Pharmaceuticals IPO investors stand to gain from the growing pharmaceutical export market. Although there are risks pertaining to contract manufacturing, the company’s financial growth and expansion plans are compelling. 

 

Finowings IPO Analysis

Hope you enjoyed the Finowings IPO Analysis. We tried our best to give every required detail about the company that you should know before applying to the IPO. 

You must consult your financial advisor before making any financial decisions. 

To Apply for the IPO, Click Here.

To Read the Prospectus of the Company Click Here to Download the DRHP.

Click Here To Stay Updated With The Upcoming IPOs.

DISCLAIMER: This blog is NOT any buy or sell recommendation. No investment or trading advice is given. The content is purely for educational and information purposes only. Always consult your eligible financial advisor for investment-related decisions.